Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
Active, not recruiting · NCT04706598 · Registry updated 2026-07-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-20 | NCT04706598 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fudan University | 653 |
| Shanghai Shen Kang Hospital Development Center | 3 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | China | 257 |
| Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine | Shanghai | China | 3 |
| Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine | Shanghai | China | 1 |
| Shanghai Tenth People's Hospital,Shanghai Tong Ji University School of Medicine | Shanghai | China | 1 |